Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): The Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study

Julio Rosenstock, B. J. Goldstein, A. I. Vinik, M. Colleen O'Neill, L. E. Porter, M. A. Heise, B. Kravitz, R. G. Dirani, M. I. Freed, Ronnie Aronson, Gordon Bailey, Makram Boctor, Philip Hardin, Carol Joyce, Andre Nadeau, Wilson Rodger, Hugh Tildesley, Vincent Woo, Jean Francois Yale, Lawrence AlwineAlan Braun, Geoffrey Burgess, Harold Kennedy Cathcart, George Chao, Andrian Dobs, Bruce Clayton Douglas, Paul Edgar, Charles Eil, J. Gary Evans, Joseph Fallon, John Gilbert Gilbert, Barry Goldstein, George Groch, Burritt Haag, Michael Harris, Scott Heatley, Priscilla Hollander, Eric Horst, Sean Hurley, Andrian James, Harvey Katzeff, William Kaye, Danny Keiller, Thomas Knecht, Daniel Lorber, Kathryn Jean Lucas, Jennifer Marks, Umesh Masharani, Mark McClanahan, James McKenney, Bernard Michlin, David Miller, Joel Neutel, Fernando Ovalle, Xavier Pi-Sunyer, Nicholas Mezitis, Mark Radbill, Sid Rosenblatt, Julio Rosenstock, Graham Scott, John Seibel, William Smith, James Synder, Alan Steckel, Roger Steinbrenner, Charles Stotler, Allen Sussman, Barbara Troupin, Jacob Vadakekalam, Aaron Vinik, Peter Winkle, Jose Yanez, Franklin Zieve

Research output: Contribution to journal › Article › peer-review

59 Scopus citations

Fingerprint

Dive into the research topics of 'Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): The Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study'. Together they form a unique fingerprint.

Medicine & Life Sciences